News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search


Immunotherapy agents set to transform melanoma treatment

Immunotherapy agents set to transform melanoma treatment

Speaking at the national Melanoma Summit in Auckland, a Los Angeles-based melanoma expert has told delegates that a new class of anti-cancer agents, known as immunotherapies, is transforming the treatment of patients with metastatic melanoma – melanoma that has spread throughout the body.

Antoni Ribas, Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles, has been the lead investigator on several large clinical trials of cutting-edge cancer treatments, including targeted therapies and immunotherapies.

Targeted therapies include BRAF and MEK inhibitors, such as vemurafenib, cobemetinib, dabrafenib and trametinib, which more precisely identify and kill cancer cells. Immunotherapies use the body’s own immune system to attack the tumour.

One group of immunotherapy agents, including the drugs pembrolizumab and nivolumab, bind to and block a molecule called PD-1 to “take the brakes off” the immune system and allow the body to detect and destroy cancer cells.

Professor Ribas says that although targeted therapies were an important advance in cancer treatment and the majority of patients obtain benefit from these agents, at least initially, there is growing evidence that immunotherapy drugs are better than other treatment strategies for a subset of patients with metastatic melanoma.

“Some patients are going for years without a relapse. We’re very conservative about how we call things, but it’s possible that some are cured.”

There is also the potential to use immunotherapies in combination with targeted agents and chemotherapy to achieve an even better response.

Professor Ribas says the advances in melanoma treatment didn’t happen by chance.

“We’re taking science from the lab to the patient and starting a series of combination studies to be able to overcome the barriers for patients who don’t respond.

“In addition to melanoma, immunotherapy has potential in a wide range of other cancers; clinical trials have studied immunotherapy agents in 30 different types of cancer, with evidence of activity in 15 of these.”


© Scoop Media

Culture Headlines | Health Headlines | Education Headlines

Obituary: Whānau Announce The Passing Of Bruce Stewart QSM

Matua Bruce was an award-winning builder before he embarked on a journey to build Tapu Te Ranga Marae in 1974... He built Tapu Te Ranga Marae from recycled material with just $25 and a dream. More>>


Gordon Campbell: On The America’s Cup

The fact New Zealand now reigns supreme once again in the most sophisticated contest in the world’s most elite sport – yacht racing – can’t help but reflect the trajectory the country has been on since the 1980s... More>>


Howard Davis: Christopher Marlowe & 'The Tragedy Of Dr. Faustus'

Previous versions of 'The Devil's Pact' can be traced back to the fourth century, Marlowe deviated significantly by depicting his protagonist as unable to burn his books or repent to a merciful God in order to have his contract annulled... More>>


Gold For RNZ: Muslim Post-9/11 Series, Kim Hill Win In New York

The Radio New Zealand podcast series Public Enemy has won a gold award for excellence for its presenter, Mohamed Hassan, at the prestigious New York Festival Radio Awards announced in Manhattan today. RNZ National’s Saturday Morning host, Kim Hill, also received a gold award for Best Radio Personality. More>>

Human Rights Commission: Give Nothing To Racism

A campaign urging New Zealanders to give nothing to racism and refuse to spread intolerance has been launched by some of the country’s most well-known people. More>>

Louis Vuitton Series Win: Emirates Team NZ Will Challenge For The America’s Cup

By beating Artemis 5-2 they now take on Oracle Team USA in the America’s Cup match starting next weekend. More>>




  • Wellington
  • Christchurch
  • Auckland